News | Cardiovascular Business | February 28, 2022

Cardiovascular Disease Concerns Pump Sales of Cardiac Markers to $2.5 Billion

Healthcare publisher, Kalorama Information, shares insights from its latest report on the Cardiac Markers market

image of a heart

February 28, 2022 – Despite improvements in treatment and increased public awareness about prevention, cardiovascular disease (CVD) is still the leading cause of death worldwide. CVD causes half of all deaths in several developed countries and is the major cause of adult death in many developing countries. And though some cardiovascular events aren't fatal, strokes and other forms of heart disease may still be debilitating enough to seriously affect functional ability. These concerns are contributing to growth in sales of cardiac markers, according to World Market for Cardiac Markers (POC and Lab-Based), a recent report by medical market research firm Kalorama Information.

Cardiac markers generated an estimated $2.52 billion in sales during 2021, largely as a result of the prevalence of cardiovascular diseases, including those of the blood vessels supplying the heart muscle and the brain. Looking ahead, the market is forecast to increase by a compound annual growth rate (CAGR) of 4.1% between 2021-2026, reveals World Market for Cardiac Markers (POC and Lab-Based).

“With the incidence of cardiovascular disease going through the roof, cardiac markers are in huge demand and a constant subject of research for improvement,” said Bruce Carlson, publisher for Kalorama Information.

Cardiac biomarkers are substances that are released into the bloodstream when the heart is damaged or stressed. In patients with chronic heart failure, measurement of these biomarkers is used to help risk stratify, to assess treatment options, monitor progress, and guide in-hospital and post-discharge care.

Physicians use cardiac markers in two ways—to diagnose a cardiac event in a hospital emergency room (acute care) or to evaluate the risk of a cardiovascular event occurring. The traditional markers—BNP, troponin and myoglobin are used in the acute care and tests such as cholesterol are used to evaluate risk.

An aging population combined with advancements in technology are innovating the market as health care providers seek ways to meet the demand for high levels of service in a more cost-effective manner.

For more information: https://kaloramainformation.com/product/world-market-for-cardiac-markers-poc-and-lab-based/.

Related cardiovascular disease content:

A Decade of Women’s Heart Health, Reexamined

Two Elevated Biomarkers Distinguish Blacks with Resistant Hypertension

Adolescent Psychological Well-being Tied to Adult Risk of Cardiovascular Disease, Study Finds


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now